Novartis in Focus. Based in Basel, Novartis (NVS) is in the Medical sector, and so far this year, shares have seen a price change of 21.05%. Currently paying a dividend of $2.6 per share, the ...

Novartis argues that it needs the court to issue its decision on the ‘918 patent case quickly because MSN has indicated it’s willing to launch at risk as soon as it has approval and isn’t ...

While the execs with Lilly and Novartis appeared curious but cautious about PD-(L)1xVEGF bispecifics, it’s worth noting that biopharma companies often present a degree of impartiality on hot ...

Failures at Novartis have prompted U.K. | Failures at Novartis have prompted the U.K. marketing watchdog to warn that “companies should be on high alert” when working with third parties to ...

June 4, 2025 . At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone ...

Today's biotech news covers Pluvicto's prostate cancer play, J&J's big bets on bladder, lung, and talent, and more.

On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu ...

Novartis is continuing to add to the body of evidence on the efficacy and safety of Kisqali in different patient populations. Trial design details will be presented at ASCO for the Adjuvant WIDER ...

At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis added that the study is ongoing with further analyses planned for tolerability and efficacy of Scemblix with a 65-event cut-off. It follows the ASC4FIRST study (NCT04971226) for efficacy in ...